Instrument Inactif

Communiqués Miragen Therapeutics Inc Nasdaq

Actions

US8266402036

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

11/06	Mise à jour sectorielle : Les actions du secteur de la santé sont mitigées en pré-marché mardi	MT
11/06	Mise à jour sectorielle : Soins de santé	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/07	AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/07	BU
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease	11/06	BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	07/06	AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/06	BU
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences	31/05	BU
Viridian Therapeutics to Participate in Upcoming May Investor Conferences	13/05	AQ
Viridian Therapeutics to Participate in Upcoming May Investor Conferences	10/05	BU
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results	08/05	BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	06/05	AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05	BU
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024	29/04	BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04	BU
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm	29/03	PR
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03	BU
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05/03	BU
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	27/02	BU
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	19/02	AQ
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	16/02	BU
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	07/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Miragen Therapeutics Inc Nasdaq

Actions

US8266402036

Communiqués

Filtres